Treatment of MIS-C in Children and Adolescents.

IF 3.6 Q1 PEDIATRICS Current pediatrics reports Pub Date : 2022-01-01 Epub Date: 2022-01-08 DOI:10.1007/s40124-021-00259-4

Sanaa Mahmoud, Mostafa El-Kalliny, Alyaa Kotby, Mona El-Ganzoury, Eman Fouda, Hanan Ibrahim

{"title":"Treatment of MIS-C in Children and Adolescents.","authors":"Sanaa Mahmoud, Mostafa El-Kalliny, Alyaa Kotby, Mona El-Ganzoury, Eman Fouda, Hanan Ibrahim","doi":"10.1007/s40124-021-00259-4","DOIUrl":null,"url":null,"abstract":"Purpose of review: Different treatment approaches have been described for the management of COVID-19-related multisystem inflammatory syndrome in children (MIS-C), the pathogenesis of which has not yet been fully elucidated. Here, we comprehensively review and summarize the recommendations and management strategies that have been published to date.Recent findings: MIS-C patients are treated with different regimens, mostly revolving around the use of immunomodulatory medications, including IVIG and glucocorticoids as first-tier therapy. Refractoriness to IVIG and glucocorticoids warrants a step-up of immunomodulatory therapy to biologic agents such as anakinra, tocilizumab, and infliximab.Summary: We review the current evidence regarding the use of monotherapy versus combination therapy, as well as the current recommendations for assessing thrombotic risk and administering antiplatelet and anticoagulant therapy. We anticipate that future studies will provide evidence for management plans that maximize short- and long-term outcomes.Supplementary information: The online version contains supplementary material available at 10.1007/s40124-021-00259-4.","PeriodicalId":72740,"journal":{"name":"Current pediatrics reports","volume":null,"pages":null},"PeriodicalIF":3.6000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8741532/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current pediatrics reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s40124-021-00259-4","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/8 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PEDIATRICS","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: Different treatment approaches have been described for the management of COVID-19-related multisystem inflammatory syndrome in children (MIS-C), the pathogenesis of which has not yet been fully elucidated. Here, we comprehensively review and summarize the recommendations and management strategies that have been published to date.

Recent findings: MIS-C patients are treated with different regimens, mostly revolving around the use of immunomodulatory medications, including IVIG and glucocorticoids as first-tier therapy. Refractoriness to IVIG and glucocorticoids warrants a step-up of immunomodulatory therapy to biologic agents such as anakinra, tocilizumab, and infliximab.

Summary: We review the current evidence regarding the use of monotherapy versus combination therapy, as well as the current recommendations for assessing thrombotic risk and administering antiplatelet and anticoagulant therapy. We anticipate that future studies will provide evidence for management plans that maximize short- and long-term outcomes.

Supplementary information: The online version contains supplementary material available at 10.1007/s40124-021-00259-4.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

治疗儿童和青少年的 MIS-C。

综述目的：COVID-19相关儿童多系统炎症综合征（MIS-C）的发病机制尚未完全阐明，目前已有不同的治疗方法。在此，我们全面回顾并总结了迄今为止已发表的建议和管理策略：MIS-C患者的治疗方案各不相同，大多围绕着免疫调节药物的使用，包括作为一级疗法的IVIG和糖皮质激素。摘要：我们回顾了目前关于使用单一疗法还是联合疗法的证据，以及目前关于评估血栓风险和进行抗血小板及抗凝治疗的建议。我们预计未来的研究将为最大限度地提高短期和长期疗效的管理计划提供证据：在线版本包含补充材料，可在 10.1007/s40124-021-00259-4上查阅。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊